Research progress in the pathogenesis and treatment of functional dyspepsia

doi:10.3877/cma.j.issn.2095-2015.2020.06.008

Abstract

Abstract:

Functional dyspepsia(FD)is a common functional gastrointestinal disease, including postprandial distress syndrome(PDS)and epigastric pain syndrome(EPS)according to RomeⅥstandard.FD has many pathophysiological mechanisms including increased visceral sensitivity, impaired gastric accommodation and delayed gastric emptying.FD is characterized by high incidence, diverse symptoms and recurrent attacks, which has negative effect on the quality of life and on the physical and psychological health of the patients.We make a complete conclusion about the pathogenesis and treatment of FD in this review.

Key words: Functional dyspepsia, Pathophysiology, Therapy

Ying Zhu, Chao Sun, Jie Chen, Lin Lin. Research progress in the pathogenesis and treatment of functional dyspepsia[J]. Chinese Journal of Digestion and Medical Imageology(Electronic Edition), 2020, 10(06): 272-278.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhxhbyyxzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-2015.2020.06.008

https://zhxhbyyxzz.cma-cmc.com.cn/EN/Y2020/V10/I06/272

References 107

1	Ford AC, Marwaha A, Sood R，et al.Global prevalence of，and risk factors for，uninvestigated dyspepsia：a meta-analysis.Gut，2015，64(7):1049-1057.
2	Stanghellini V, Chan FK, Hasler WL，et al.Gastroduodenal Disorders.Gastroenterology，2016，150(6):1380-1392.
3	Futagami S, Yamawaki H, Agawa S，et al.New classification Rome IV functional dyspepsia and subtypes.Transl Gastroenterol Hepatol，2018，3:70-72.
4	Futagami S, Yamawaki H, Hashimoto S，et al.New horizon of the pathophysiology of functional dyspepsia.Nihon Shokakibyo Gakkai Zasshi，2016，113(6):927-935.
5	Camilleri M, Stanghellini V．Current management strategies and emerging treatments for functional dyspepsia.Nat Rev Gastroenterol Hepatol，2013，10(3):187-194.
6	Lacy BE, Talley NJ, Locke GR, 3rd，et al.Review article：current treatment options and management of functional dyspepsia.Aliment Pharmacol Ther，2012，36(1):3-15.
7	Takahashi T．Interdigestive migrating motor complex-its mechanism and clinical importance.J Smooth Muscle Res，2013，49:99-111.
8	Takahashi T．Mechanism of interdigestive migrating motor complex.J Neurogastroenterol Motil，2012，18(3):246-257.
9	Asano H, Tomita T, Nakamura K，et al.Prevalence of Gastric Motility Disorders in Patients with Functional Dyspepsia.J Neurogastroenterol Motil，2017，23(3):392-399.
10	Pittayanon R, Yuan Y, Bollegala NP，et al.Prokinetics for Functional Dyspepsia：A Systematic Review and Meta-Analysis of Randomized Control Trials.Am J Gastroenterol，2019，114(2):233-243.
11	Janssen P, Harris MS, Jones M，et al.The relation between symptom improvement and gastric emptying in the treatment of diabetic and idiopathic gastroparesis.Am J Gastroenterol，2013，108(9):1382-1391.
12	Current Opinion in Gastroenterology.Current world literature.Curr Opin Gastroenterol，2009，25(1):74-85.
13	Keohane J, Quigley EM.Functional dyspepsia：the role of visceral hypersensitivity in its pathogenesis.World J Gastroenterol，2006，12(17):2672-2676.
14	Hammer J, Fuhrer M, Pipal L，et al.Hypersensitivity for capsaicin in patients with functional dyspepsia.Neurogastroenterol Motil，2008，20(2):125-133.
15	Grundy D．5-HT system in the gut：roles in the regulation of visceral sensitivity and motor functions.Eur Rev Med Pharmacol Sci，2008，12 Suppl 1:63-67.
16	Geeraerts B, Vandenberghe J, Van Oudenhove L，et al.Influence of experimentally induced anxiety on gastric sensorimotor function in humans.Gastroenterology，2005，129(5):1437-1444.
17	Ma G, Hu P, Zhang B，et al.Transcutaneous electrical acustimulation synchronized with inspiration improves gastric accommodation impaired by cold stress in healthy subjects.Neurogastroenterol Motil，2019，31(2):e13491.
18	Van Oudenhove L, Vandenberghe J, Geeraerts B，et al.Determinants of symptoms in functional dyspepsia：gastric sensorimotor function，psychosocial factors or somatisation? Gut，2008，57(12):1666-1673.
19	Geeraerts B, Van Oudenhove L, Fischler B，et al.Influence of abuse history on gastric sensorimotor function in functional dyspepsia.Neurogastroenterol Motil，2009，21(1):33-41.
20	Hartono JL, Mahadeva S, Goh KL.Anxiety and depression in various functional gastrointestinal disorders：do differences exist? J Dig Dis，2012，13(5):252-257.
21	Bouchoucha M, Hejnar M, Devroede G，et al.Anxiety and depression as markers of multiplicity of sites of functional gastrointestinal disorders：a gender issue? Clin Res Hepatol Gastroenterol，2013，37(4):422-430.
22	Browning KN, Travagli RA.Central nervous system control of gastrointestinal motility and secretion and modulation of gastrointestinal functions.Compr Physiol，2014，4(4):1339-1368.
23	Koloski NA, Jones M, Kalantar J，et al.The brain--gut pathway in functional gastrointestinal disorders is bidirectional：a 12-year prospective population-based study.Gut，2012，61(9):1284-1290.
24	Liu P, Wang G, Zeng F，et al.Abnormal brain structure implicated in patients with functional dyspepsia.Brain Imaging Behav，2018，12(2):459-466.
25	Lee KJ, Tack J．Duodenal implications in the pathophysiology of functional dyspepsia.J Neurogastroenterol Motil，2010，16(3):251-257.
26	Miwa H, Oshima T, Tomita T，et al.Recent understanding of the pathophysiology of functional dyspepsia：role of the duodenum as the pathogenic center.J Gastroenterol，2019，54(4):305-311.
27	Lee KJ, Demarchi B, Demedts I，et al.A pilot study on duodenal acid exposure and its relationship to symptoms in functional dyspepsia with prominent nausea.Am J Gastroenterol，2004，99(9):1765-1773.
28	Bratten J, Jones MP.Prolonged recording of duodenal acid exposure in patients with functional dyspepsia and controls using a radiotelemetry pH monitoring system.J Clin Gastroenterol，2009，43(6):527-533.
29	Bharucha AE, Camilleri M, Burton DD，et al.Increased nutrient sensitivity and plasma concentrations of enteral hormones during duodenal nutrient infusion in functional dyspepsia.Am J Gastroenterol，2014，109(12):1910-1920.
30	Oshima T, Okugawa T, Tomita T，et al.Generation of dyspeptic symptoms by direct acid and water infusion into the stomachs of functional dyspepsia patients and healthy subjects.Aliment Pharmacol Ther，2012，35(1):175-182.
31	Vanheel H, Vicario M, Vanuytsel T，et al.Impaired duodenal mucosal integrity and low-grade inflammation in functional dyspepsia.Gut，2014，63(2):262-271.
32	Tanaka F, Tominaga K, Fujikawa Y，et al.Concentration of Glial Cell Line-Derived Neurotrophic Factor Positively Correlates with Symptoms in Functional Dyspepsia.Dig Dis Sci，2016，61(12):3478-3485.
33	Du L, Shen J, Kim JJ，et al.Increased Duodenal Eosinophil Degranulation in Patients with Functional Dyspepsia：A Prospective Study.Sci Rep，2016，6:34305.
34	Osadchiy V, Martin CR, Mayer EA.The Gut-Brain Axis and the Microbiome：Mechanisms and Clinical Implications.Clin Gastroenterol Hepatol，2019，17(2):322-332.
35	Quigley EMM.The Gut-Brain Axis and the Microbiome：Clues to Pathophysiology and Opportunities for Novel Management Strategies in Irritable Bowel Syndrome(IBS)．J Clin Med，2018，7(1):6-13.
36	Zhong L, Shanahan ER, Raj A，et al.Dyspepsia and the microbiome：time to focus on the small intestine.Gut，2017，66(6):1168-1169.
37	Igarashi M, Nakae H, Matsuoka T，et al.Alteration in the gastric microbiota and its restoration by probiotics in patients with functional dyspepsia.BMJ Open Gastroenterol，2017，4(1):e000144.
38	Lembo A, Pimentel M, Rao SS，et al.Repeat Treatment With Rifaximin Is Safe and Effective in Patients With Diarrhea-Predominant Irritable Bowel Syndrome.Gastroenterology，2016，151(6):1113-1121.
39	Kimer N, Krag A, Moller S，et al.Systematic review with meta-analysis：the effects of rifaximin in hepatic encephalopathy.Aliment Pharmacol Ther，2014，40(2):123-132.
40	Tan VP, Liu KS, Lam FY，et al.Randomised clinical trial：rifaximin versus placebo for the treatment of functional dyspepsia.Aliment Pharmacol Ther，2017，45(6):767-776.
41	Mazzoleni LE, Sander GB, Francesconi CF，et al.Helicobacter pylori eradication in functional dyspepsia：HEROES trial.Arch Intern Med，2011，171(21):1929-1936.
42	Kim SE, Park YS, Kim N，et al.Effect of Helicobacter pylori Eradication on Functional Dyspepsia.J Neurogastroenterol Motil，2013，19(2):233-243.
43	Lan L, Yu J, Chen YL，et al.Symptom-based tendencies of Helicobacter pylori eradication in patients with functional dyspepsia.World J Gastroenterol，2011，17(27):3242-3247.
44	Xu S, Wan X, Zheng X，et al.Symptom improvement after helicobacter pylori eradication in patients with functional dyspepsia-A multicenter，randomized，prospective cohort study.Int J Clin Exp Med，2013，6(9):747-756.
45	Sugano K, Tack J, Kuipers EJ, faculty members of Kyoto Global Consensus C．Kyoto global consensus report on Helicobacter pylori gastritis.Gut，2015，64(9):1353-1367.
46	Talley NJ, Ford AC.Functional Dyspepsia.N Engl J Med，2015，373(19):1853-1863.
47	Jodaki A, Sahraie A, Yasemi M，et al.Helicobacter pylori eradication effect on patients with functional dyspepsia symptoms.Minerva Gastroenterol Dietol，2016，62(2):148-154.
48	Zhao W, Zhong X, Zhuang X，et al.Evaluation of Helicobacter pylori eradication and drug therapy in patients with functional dyspepsia.Exp Ther Med，2013，6(1):37-44.
49	Tack J, Camilleri M．New developments in the treatment of gastroparesis and functional dyspepsia.Curr Opin Pharmacol，2018，43:111-117.
50	Masuy I, Van Oudenhove L, Tack J．Review article：treatment options for functional dyspepsia.Aliment Pharmacol Ther，2019，49(9):1134-1172.
51	Hongo M, Harasawa S, Mine T，et al.Large-scale randomized clinical study on functional dyspepsia treatment with mosapride or teprenone：Japan Mosapride Mega-Study(JMMS)．J Gastroenterol Hepatol，2012，27(1):62-68.
52	Curran MP, Robinson DM.Mosapride in gastrointestinal disorders.Drugs，2008，68(7):981-991.
53	Uchida M, Yamato S, Shimizu K，et al.Dual role of mosapride citrate hydrate on the gastric emptying evaluated by the breath test in conscious rats.J Pharmacol Sci，2013，121(4):282-287.
54	Keto Y, Hirata T, Takemoto Y，et al.Influence of gastric acid on gastric emptying and gastric distension-induced pain response in rats--effects of famotidine and mosapride.Neurogastroenterol Motil，2012，24(2):147-153.
55	Masuy I, Carbone F, Holvoet L，et al.The effect of rikkunshito on gastrointestinal symptoms and gastric motor function：The first study in a Belgian functional dyspepsia population.Neurogastroenterol Motil，2020，32(2):e13739.
56	Hallerback BI, Bommelaer G, Bredberg E，et al.Dose finding study of mosapride in functional dyspepsia：a placebo-controlled，randomized study.Aliment Pharmacol Ther，2002，16(5):959-967.
57	Tack J, Van den Houte K, Carbone F．The Unfulfilled Promise of Prokinetics for Functional Dyspepsia/Postprandial Distress Syndrome.Am J Gastroenterol，2019，114(2):204-206.
58	Hiyama T, Yoshihara M, Matsuo K，et al.Treatment of functional dyspepsia with serotonin agonists：a meta-analysis of randomized controlled trials.J Gastroenterol Hepatol，2007，22(10):1566-1570.
59	Tegaserod：withdrawal from the world market.A treatment for constipation with cardiovascular adverse effects.Prescrire Int，2008，17(95):112-113.
60	Griffin JP.Prepulsid withdrawn from UK & US markets.Adverse Drug React Toxicol Rev，2000，19(3):177.
61	Ehlert FJ, Pak KJ, Griffin MT.Muscarinic agonists and antagonists：effects on gastrointestinal function.Handb Exp Pharmacol，2012，(208):343-374.
62	Ikeo K, Oshima T, Sei H，et al.Acotiamide improves stress-induced impaired gastric accommodation.Neurogastroenterol Motil，2017，29(4):e12991.
63	Shinozaki S, Osawa H, Sakamoto H，et al.The effect of acotiamide on epigastric pain syndrome and postprandial distress syndrome in patients with functional dyspepsia.J Med Invest，2016，63(3-4):230-235.
64	Ogishima M, Kaibara M, Ueki S，et al.Z-338 facilitates acetylcholine release from enteric neurons due to blockade of muscarinic autoreceptors in guinea pig stomach.J Pharmacol Exp Ther，2000，294(1):33-37.
65	Altan E, Masaoka T, Farre R，et al.Acotiamide，a novel gastroprokinetic for the treatment of patients with functional dyspepsia：postprandial distress syndrome.Expert Rev Gastroenterol Hepatol，2012，6(5):533-544.
66	Matsueda K, Hongo M, Tack J，et al.A placebo-controlled trial of acotiamide for meal-related symptoms of functional dyspepsia.Gut，2012，61(6):821-828.
67	Veldhuyzen van Zanten SJ, Chiba N，et al.A randomized trial comparing omeprazole，ranitidine，cisapride，or placebo in helicobacter pylori negative，primary care patients with dyspepsia：the CADET-HN Study.Am J Gastroenterol，2005，100(7):1477-1488.
68	Sakurai K, Nagahara A, Inoue K，et al.Efficacy of omeprazole，famotidine，mosapride and teprenone in patients with upper gastrointestinal symptoms：an omeprazole-controlled randomized study(J-FOCUS)．BMC Gastroenterol，2012，12:42-53.
69	Moayyedi P, Delaney BC, Vakil N，et al.The efficacy of proton pump inhibitors in nonulcer dyspepsia：a systematic review and economic analysis.Gastroenterology，2004，127(5):1329-1337.
70	Pinto-Sanchez MI, Yuan Y, Hassan A，et al.Proton pump inhibitors for functional dyspepsia.Cochrane Database Syst Rev，2017，11(11):CD011194.
71	Laine L, Ahnen D, McClain C，et al.Review article：potential gastrointestinal effects of long-term acid suppression with proton pump inhibitors.Aliment Pharmacol Ther，2000，14(6):651-668.
72	Tougas G, Earnest DL, Chen Y，et al.Omeprazole delays gastric emptying in healthy volunteers：an effect prevented by tegaserod.Aliment Pharmacol Ther，2005，22(1):59-65.
73	Van Oudenhove L, Vandenberghe J, Geeraerts B，et al.Relationship between anxiety and gastric sensorimotor function in functional dyspepsia.Psychosom Med，2007，69(5):455-463.
74	Farre R, Vanheel H, Vanuytsel T，et al.In functional dyspepsia，hypersensitivity to postprandial distention correlates with meal-related symptom severity.Gastroenterology，2013，145(3):566-573.
75	Jones MP, Talley NJ, Eslick GD，et al Community subgroups in dyspepsia and their association with weight loss.Am J Gastroenterol，2008，103(8):2051-2060.
76	Simren M, Tornblom H, Palsson OS，et al.Visceral hypersensitivity is associated with GI symptom severity in functional GI disorders：consistent findings from five different patient cohorts.Gut，2018，67(2):255-262.
77	Tack J, Broekaert D, Coulie B，et al.Influence of the selective serotonin re-uptake inhibitor，paroxetine，on gastric sensorimotor function in humans.Aliment Pharmacol Ther，2003，17(4):603-608.
78	Chial HJ, Camilleri M, Burton D，et al.Selective effects of serotonergic psychoactive agents on gastrointestinal functions in health.Am J Physiol Gastrointest Liver Physiol，2003，284(1):G130-137.
79	Talley NJ, Locke GR, Saito YA，et al.Effect of Amitriptyline and Escitalopram on Functional Dyspepsia：A Multicenter，Randomized Controlled Study.Gastroenterology，2015，149(2):340-349.
80	Drossman DA, Tack J, Ford AC，et al.Neuromodulators for Functional Gastrointestinal Disorders(Disorders of Gut-Brain Interaction)：A Rome Foundation Working Team Report.Gastroenterology，2018，154(4):1140-1171.
81	Kim BJ, Kuo B．Gastroparesis and Functional Dyspepsia：A Blurring Distinction of Pathophysiology and Treatment.J Neurogastroenterol Motil，2019，25(1):27-35.
82	Potter MDE, Goodsall TM, Walker MM，et al.Dual histamine blockade for the treatment of adult functional dyspepsia：a single centre experience.Gut，2020，69(5):966.
83	Friesen CA, Sandridge L, Andre L，et al.Mucosal eosinophilia and response to H1/H2 antagonist and cromolyn therapy in pediatric dyspepsia.Clin Pediatr(Phila)，2006，45(2):143-147.
84	Friesen CA, Kearns GL, Andre L，et al.Clinical efficacy and pharmacokinetics of montelukast in dyspeptic children with duodenal eosinophilia.J Pediatr Gastroenterol Nutr，2004，38(3):343-351.
85	Potter MDE, Wood NK, Walker MM，et al.Proton pump inhibitors and suppression of duodenal eosinophilia in functional dyspepsia.Gut，2019，68(7):1339-1340.
86	Tack J, Talley NJ, Camilleri M，et al.Functional gastroduodenal disorders.Gastroenterology，2006，130(5):1466-1479.
87	Duncanson KR, Talley NJ, Walker MM，et al.Food and functional dyspepsia：a systematic review.J Hum Nutr Diet，2018，31(3):390-407.
88	Acker BW, Cash BD.Medicinal Foods for Functional GI Disorders.Curr Gastroenterol Rep，2017，19(12):62-69.
89	Ciampa BP, Reyes Ramos E, Borum M，et al.The Emerging Therapeutic Role of Medical Foods for Gastrointestinal Disorders.Gastroenterol Hepatol(N Y)，2017，13(2):104-115.
90	Zeng F, Qin W, Ma T，et al.Influence of acupuncture treatment on cerebral activity in functional dyspepsia patients and its relationship with efficacy.Am J Gastroenterol，2012，107(8):1236-1247.
91	Aro P, Talley NJ, Ronkainen J，et al.Anxiety is associated with uninvestigated and functional dyspepsia(Rome III criteria)in a Swedish population-based study.Gastroenterology，2009，137(1):94-100.
92	Hsu YC, Liou JM, Liao SC，et al.Psychopathology and personality trait in subgroups of functional dyspepsia based on Rome III criteria.Am J Gastroenterol，2009，104(10):2534-2542.
93	Gathaiya N, Locke GR, 3rd, Camilleri M，et al.Novel associations with dyspepsia：a community-based study of familial aggregation，sleep dysfunction and somatization.Neurogastroenterol Motil，2009，21(9):922-e69.
94	Ford AC, Moayyedi P, Lacy BE, Task Force on the Management of Functional Bowel D．American College of Gastroenterology monograph on the management of irritable bowel syndrome and chronic idiopathic constipation.Am J Gastroenterol，2014，109 Suppl 1:S2-26.
95	Calvert EL, Houghton LA, Cooper P，et al.Long-term improvement in functional dyspepsia using hypnotherapy.Gastroenterology，2002，123(6):1778-1785.
96	Orive M, Barrio I, Orive VM，et al.A randomized controlled trial of a 10 week group psychotherapeutic treatment added to standard medical treatment in patients with functional dyspepsia.J Psychosom Res，2015，78(6):563-568.
97	Dehghanizade Z, Zargar Y, Mehrabizadeh Honarmand M，et al.The effectiveness of cognitive behavior stress management on functional dyspepsia symptoms.J Adv Med Educ Prof，2015，3(2):45-49.
98	Faramarzi M, Azadfallah P, Book HE，et al.A randomized controlled trial of brief psychoanalytic psychotherapy in patients with functional dyspepsia.Asian J Psychiatr，2013，6(3):228-234.
99	Hamilton J, Guthrie E, Creed F，et al.A randomized controlled trial of psychotherapy in patients with chronic functional dyspepsia.Gastroenterology，2000，119(3):661-669.
100	Xu F, Tan Y, Huang Z，et al.Ameliorating Effect of Transcutaneous Electroacupuncture on Impaired Gastric Accommodation in Patients with Postprandial Distress Syndrome-Predominant Functional Dyspepsia：A Pilot Study.Evid Based Complement Alternat Med，2015，2015:168252.
101	Zhang N, Huang Z, Xu F，et al.Transcutaneous Neuromodulation at Posterior Tibial Nerve and ST36 for Chronic Constipation.Evid Based Complement Alternat Med，2014，2014:560802.
102	Liu Z, Lu D, Guo J，et al.Elevation of Lower Esophageal Sphincter Pressure With Acute Transcutaneous Electrical Acustimulation Synchronized With Inspiration.Neuromodulation，2019，22(5):586-592.
103	Lorena SL, Figueiredo MJ, Almeida JR，et al.Autonomic function in patients with functional dyspepsia assessed by 24-hour heart rate variability.Dig Dis Sci，2002，47(1):27-31.
104	Chen J, Song GQ, Yin J，et al.Electroacupuncture improves impaired gastric motility and slow waves induced by rectal distension in dogs.Am J Physiol Gastrointest Liver Physiol，2008，295(3):G614-620.
105	Ouyang H, Yin J, Wang Z，et al.Electroacupuncture accelerates gastric emptying in association with changes in vagal activity.Am J Physiol Gastrointest Liver Physiol，2002，282(2):G390-396.
106	Liu S, Peng S, Hou X，et al.Transcutaneous electroacupuncture improves dyspeptic symptoms and increases high frequency heart rate variability in patients with functional dyspepsia.Neurogastroenterol Motil，2008，20(11):1204-1211.
107	Ji T, Li X, Lin L，et al.An alternative to current therapies of functional dyspepsia：self-administrated transcutaneous electroacupuncture improves dyspeptic symptoms.Evid Based Complement Alternat Med，2014，2014:832523.

[1]	The Joint Surgery Branch of the Chinese Orthopedic Association, Guangdong’s Medical Association of Osteoporosis And Bone Mineral Research, Foshan Shunde 3rd Peoele’s Hospital. Clinical intervention guideline for using of anti-osteoporosis drugs in postoperative fragile hip fractures in China (2023 Edition) [J]. Chinese Journal of Joint Surgery(Electronic Edition), 2023, 17(06): 751-764.
[2]	Zeying Jiang, Anting Wang, Jiaoli Wang, Ci Chen, Qiuling Zhou, Yanjuan Huang, Fang Zhou, Yan Xue, Jianfeng Zhou, Wenyong Tan, Meifang Du. Effect of multiple plant oils combination in preventing the chemoradiotherapy induced toxicities [J]. Chinese Journal of Injury Repair and Wound Healing(Electronic Edition), 2023, 18(06): 523-527.
[3]	Wei Zhang. Dentoalveolar surgery: The pioneer of comfortable treatment [J]. Chinese Journal of Stomatological Research(Electronic Edition), 2023, 17(06): 386-388.
[4]	Dechen Wang, Kang Yang, Zijie Yang, Mingbin Gui, Lianping Qu, Xiaofeng Zhang, Feng Gao. Progress of microsatellite stability state and PD-1/PD-L1/IDO in colorectal carcinoma [J]. Chinese Archives of General Surgery(Electronic Edition), 2023, 17(06): 462-465.
[5]	Yanhui Zhang, Jiao Zhang, Zhixian Zhu. Effect of indwelling anal tube on anastomotic leakage after laparoscopic total mesangectomy after neoadjuvant chemoradiotherapy in patients with middle and low rectal cancer [J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2024, 18(01): 25-28.
[6]	Zhibo Gu, lin Hao, Ming Lu, Jiangang Chen. Photodynamic nanocarriers combined with siP3H4 for precise targeting therapy in the treatment of bladder cancer: a pilot study [J]. Chinese Journal of Endourology(Electronic Edition), 2023, 17(06): 633-641.
[7]	Bo Kong, Jing Zhang, Ke Lyu. Review on the role of ultrasonography in the diagnosis and treatment of complex ventral hernia [J]. Chinese Journal of Hernia and Abdominal Wall Surgery(Electronic Edition), 2023, 17(06): 670-673.
[8]	Xilin Du, Kai Tan, Xiaojun He. Conversion therapies for hepatocellular carcinoma [J]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2023, 12(06): 597-601.
[9]	Xiaoyong Wei. Discussion on the focus issues of conversion therapy for primary liver cancer [J]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2023, 12(06): 602-607.
[10]	Chenrui Wu, Rui Liao, Qiang He. Hepatic arterial infusion chemotherapy combined immunotargeted therapy for multiple metastatic hepatocellular carcinoma in a multi-disciplinary treatment model: a case report [J]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2023, 12(06): 713-716.
[11]	Huiying Ma, Xinling Fan, Shirui Tan, Jiayun Chen, Ying Cao, Yuan Xu, Jing Jin, Yuan Tang. Magnetic resonance linac for locally advanced rectal cancer: a preliminary experience [J]. Chinese Journal of Colorectal Diseases(Electronic Edition), 2023, 12(06): 519-523.
[12]	Guangjun Zhong, Chunhua Liu, Wansen Zhu, Xiaolei Xu, Zhaojun Wang. Application of conventional MRI combined with different scanning sequences in preoperative staging diagnosis, chemotherapy efficacy and prognosis evaluation of gastric cancer [J]. Chinese Journal of Digestion and Medical Imageology(Electronic Edition), 2023, 13(06): 378-382.
[13]	Ruixue Yue, Lingxin Kong, Xin Hao, Jinqiang Yang, Meng Han, Guozhong Cui, Jianjun Wang, Zhisheng Zhang, Fanting Kong, Wei Zhang, Wenbo He, Xianqiao Li, Xinping Zhou, Donghong Xu, Chongzhu Hu. HER2 protein expression levels predict efficacy of neoadjuvant therapy in breast cancer: A real-world study [J]. Chinese Journal of Clinicians(Electronic Edition), 2023, 17(07): 765-770.
[14]	Yingqian Li, Huashan Li. Evaluation of treatment methods for complete rectal prolapse: a real world study [J]. Chinese Journal of Clinicians(Electronic Edition), 2023, 17(06): 700-705.
[15]	Meisha Fu, Yuhua Zhou, Hui Li, Chunyan Xue. Effect of lymphocyte immunotherapy on T lymphocyte subset distribution and PD1/PD-L1 expression in patients with recurrent miscarriage [J]. Chinese Journal of Clinicians(Electronic Edition), 2023, 17(06): 726-730.

Please choose a citation manager

Content to export